Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
imatinib (400 mg) plus pioglitazone (15 mg) daily for six months, with follow-up extending to 60 months
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These results suggest that pioglitazone may enhance early molecular response and suppress LSC-associated genes, but further research is needed to confirm its long-term benefit and clarify the role of PPARγ modulation in CML management. NCT04883125.
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML), yet persistent leukemia stem cells (LSCs) remain a barrier to cure.
- 추적기간 60 months
APA
Atef B, El-Ashwah S, et al. (2026). Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells.. Annals of hematology, 105(4). https://doi.org/10.1007/s00277-026-06795-7
MLA
Atef B, et al.. "Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells.." Annals of hematology, vol. 105, no. 4, 2026.
PMID
41735647 ↗
Abstract 한글 요약
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML), yet persistent leukemia stem cells (LSCs) remain a barrier to cure. PPARγ agonists like pioglitazone have been proposed to enhance eradication of LSCs when used alongside TKIs. This study investigated the impact of adding pioglitazone to imatinib therapy in 26 newly diagnosed chronic-phase CML patients. Patients received imatinib (400 mg) plus pioglitazone (15 mg) daily for six months, with follow-up extending to 60 months. Treatment responses and adverse events were recorded, and expression levels of and genes were measured before and after therapy, compared to a control group of 52 matched patients treated with imatinib alone. The combination therapy showed improved early cytogenetic and molecular responses, though long-term outcomes were not significantly different. Significant reductions in median (from 276.3 to 2.6; = 0.005) and (from 2.7 to 1; = 0.026) expression were observed post-treatment. These results suggest that pioglitazone may enhance early molecular response and suppress LSC-associated genes, but further research is needed to confirm its long-term benefit and clarify the role of PPARγ modulation in CML management. NCT04883125.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review.
- Restless legs syndrome in chronic myeloid leukemia: an overlooked condition with a significant impact on health-related quality of life.
- Leukemia during pregnancy and survivorship: gestational age-stratified multidisciplinary management framework.
- AML with t(8;21): A Molecularly Defined Entity with Morphological Ambiguities.
- Immune Surveillance in Chronic Myeloid Leukemia: Tumor Antigen Expression and CD8 T Cell Function in the Context of Treatment- Free Remission.
- Multimodal gene and targeted drug therapy for chronic myelogenous leukemia using BIM/MCL-1 chimeric nanoparticle: computational target analysis and therapeutic validation.